Decoding GLP-1 Weight Loss Medications
US$ 25.31
glp-1 class drugs Comparing Ozempic, Wegovy and Other GLP-1 Safety Check - National
Description
Strategic nutrition becomes critical
In addition, the SUMMIT trial evaluates the effect of tirzepatide (the GLP-1/GIP dual receptor agonist) in people with obesity-related HFpEF (Clinicaltrials.gov ID NCT04847557)
[DOI] [PubMed] [Google Scholar] 85.Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C
J., Nian C., McIntosh C
served on scientific advisory panels and/or speakers bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi
AlAtram A
